Wright State University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Dayton OH United States (1967)

Organization Overview

First Clinical Trial
2002
NCT00161759
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Jeffrey B. Travers, MD, PhD | Wright State Physicians | Wright State Physicians Pharmacology Translational Unit | Wright State University | Wright State University Boonshoft School of Medicine, Dayton, OH | Wright State University, Children's Medical Center of Dayton | Wright State University, Dayton, Ohio | Wright State University, Miami Valley Hospital, Dayton, OH

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Burns (Phase 2)

Dermatitis (Phase 1)

Dermatitis, Allergic Contact (Phase 1)

Dermatitis, Contact (Phase 1)

Hypersensitivity (Phase 1)

Hypersensitivity, Delayed (Phase 1)

Hypertension (Phase 4)

Hypertension, Pregnancy-Induced (Phase 4)

Irritable Bowel Syndrome (Phase 1)

Keratosis (Phase 1)

Keratosis, Actinic (Phase 1)

Kidney Failure, Chronic (Phase 4)

Lichen Planus (Phase 2)

Pain, Postoperative (Phase 4)

Pneumonia (Phase 4)

Pneumonia, Ventilator-Associated (Phase 4)

Psoriasis (Phase 1)

Pyoderma (Phase 2)

Pyoderma Gangrenosum (Phase 2)

Renal Insufficiency (Phase 2)

Sarcoidosis (Phase 2)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial APIs: 38